Hangzhou Arno Biopharmaceutical Technology Co., Ltd. (stock code: NASDAQ: ANL) successfully listed on NASDAQ on September 29, 2023. The company is a global biopharmaceutical company in clinical development, with R&D and clinical operation centers in both China and the United States. It has built multiple global product pipelines through the models of "joint innovation" and "independent research and development." Among them, AN2025 (buparlisib) has obtained the FDA's Fast Track designation. Its combination with paclitaxel is expected to become the first drug for the treatment of second-line relapsed or metastatic HNSCC after PD-1 failure, and a global multi-center Phase III clinical trial is underway; AN0025 (palupiprant) is an EP4 antagonist expected to treat solid tumors by regulating the tumor microenvironment and is currently in collaboration with Keytruda.®The Ib clinical trial phase for the combined treatment of patients with multiple solid tumors; AN4005 is an independently developed oral small molecule PD-L1 inhibitor. Currently, Phase I clinical trials are being conducted simultaneously in China and the United States to determine safety, tolerability, and the recommended Phase II dose (RP2D). Frost & Sullivan (Frost & Sullivan, hereinafter referred to as 'Frost & Sullivan') provides exclusive industry advisory services for the listing of Anuo Biopharmaceutical Technology Co., Ltd. We hereby extend our warm congratulations on its successful listing.
Hangzhou Anuo Biomedical Technology Co., Ltd. (hereinafter referred to as 'Anuo Medicine') successfully went public on September 29, 2023, issuing 4.614 million ADSs at a price of $23 per share. It is expected to raise up to $106.1 million in funds, of which $57.5 million will come from public offerings (excluding underwriting discounts, commissions, and issuance expenses, without considering the potential exercise of underwriter's over-allotment options), $40 million from private placements during the same period, and $8.6 million from the exercise of all over-allotment rights.
During the process of listing in the US, Frost & Sullivan mainly undertook the following tasks: helping the issuer accurately and objectively understand its positioning in the target market, using objective market data to discover, support, and highlight the issuer's competitive advantages, assisting the issuer, sponsor, and other professional intermediary institutions in completing the writing of relevant parts of the prospectus (such as overview, competitive advantages and strategy, industry overview, business, and other important sections), helping the issuer communicate with the SEC and investors, assisting investors in quickly understanding the market ecosystem and competitive landscape, and assisting the issuer in completing feedback on industry-related issues from the SEC.
Investment highlights
The company has a rich pipeline of products, including multiple innovative candidate drugs targeting a range of tumor indications;
The company has secured solid Phase II data to ensure the successful registration;
The company targets unmet medical needs, possessing a huge potential market size;
The company has strong R&D capabilities and has established two drug discovery platforms, namely PAINT-2D™ and ANEAT-Id™.
The company has a sustainable patent portfolio in key countries and regions;
The company has the participation of senior industry professionals and strong shareholder support.
According to the Frost & Sullivan report, the company:
AN2025 is currently the fastest-progressing PI3K inhibitor for the treatment of recurrent/metastatic head and neck squamous cell carcinoma globally, with only it having reached phase III clinical trials worldwide.
AN0025 can increase the activity of CD8+ cells and the immune response of T cells against tumors, potentially altering the immunosuppressive characteristics of the tumor microenvironment and addressing unmet needs in the treatment of various cancer types.
The clinical study of the combination therapy of AN2025, AN0025, and atezolizumab is the first of its kind in the industry for the treatment of advanced solid tumors, combining PI3K inhibitors, EP4 antagonists, and checkpoint inhibitors. It represents a potential new treatment strategy that is expected to address issues such as current resistance or low response rates to PD-1/PD-L1 inhibitors.
AN4005 is an orally administered small molecule PD-L1 inhibitor developed by the company, which is expected to offer many benefits over antibodies, such as being suitable for oral administration, having lower production costs, higher tumor penetration, and being non-immunogenic. This could potentially solve the problem of increasing immune-related adverse events in current antibody-based therapies.
In the field of oncology treatment, Frost & Sullivan has served companies such as BeiGene, Innovent Biologics, Junshi Biosciences, Rongchang Biosciences, and Kangfang Biosciences.
